Reasons for performing study: It is accepted among equine practitioners that glucocorticoid treatment is a risk factor for the development of laminitis. However, there is little published evidence of a link between glucocorticoids and laminitis. Objectives: To determine whether horses receiving oral prednisolone are at increased risk of laminitis. Study design: Retrospective case-control study. Methods: Clinical records of horses registered with the ambulatory service at Liphook Equine Hospital between January 2001 and November 2014 were reviewed retrospectively to identify horses that had received treatment with oral prednisolone. For each treated horse, 2 time-matched controls that received veterinary attention but were not treated with prednisolone were selected. Incidence of laminitis was compared between the 2 groups and factors associated with laminitis were assessed using Cox regression analysis. Results: Of the 416 horses treated with prednisolone, 16 (3.8%) were diagnosed with laminitis subsequent to the initiation of prednisolone treatment with an overall incidence of 2.60 (95% CI 1.49-4.22) cases per 100 horse-years at risk. A total of 7 horses (1.7%) developed laminitis during the course of their treatment and 3 (0.7%) of the horses treated with prednisolone were ultimately subjected to euthanasia as a result of laminitis. A total of 46 (5.7%), of the 814 time-matched control horses were diagnosed with laminitis during the study period with an overall incidence of 3.46 (95% CI 2.54-4.62) cases per 100 horse-years at risk. Of these, 12 (1.5%) were subjected to euthanasia as a result of laminitis. There were no significant differences in the overall laminitis incidence rate (P = 0.8), incidence rate during prednisolone treatment (P = 0.09), or probability of laminitis (P = 0.3) between the 2 groups. Mean survival time was greater in the prednisolone than the control group. Equine metabolic syndrome and increasing age were associated with increased risk of laminitis. Conclusions: Administration of oral prednisolone did not increase the risk of laminitis.
Introduction
Glucocorticoids have been used for more than 35 years in equine practice [1] . However, their use has been accompanied by a perception of risk of inducing laminitis [1] [2] [3] . Although the association between glucocorticoid use and induction of laminitis has been reported, a direct causal link has not been established. Explanations of the mechanism by which laminitis may be induced have included potentiation of the vasoconstrictive actions of catecholamines on large digital vessels [4, 5] , lamellar weakening due to protein catabolism [3] , insufficient glucose supply to keratinocytes [2, 6] and increased intestinal permeability to toxins [7] . It has also been proposed that there may be an indirect link via insulin dysregulation and hyperinsulinaemia, which is recognised as a factor in the development of laminitis [8] .
There have been several reports of the risk of laminitis following triamcinolone administration [9] [10] [11] [12] . In a retrospective, uncontrolled study, only 2% of 205 cases were diagnosed with laminitis prior or subsequent to glucocorticoid treatment [9] . Only one of the cases (0.5%) was considered to be related directly to triamcinolone administration. Bathe [10] reported an incidence of 0.15% following intra-articular administration of glucocorticoid over a 2 year period but again these data lacked a control population [10] . In a study of the pharmacokinetics of triamcinolone and the associated risk of laminitis, 5 horses were injected with triamcinolone intravenously and intramuscularly. Over the 2-14 month follow-up period, subclinical laminitis (in the form of lamellar rings) developed in 4 of the 5 subjects [11] .
In most countries, dexamethasone and prednisolone are the only medications licensed for systemic administration in horses and both are used widely. Given their medium-to long-term use, a higher incidence of laminitis would be expected compared with a single administration of triamcinolone. Despite their frequent use in equine practice, reports of laminitis following the use of prednisolone or dexamethasone are limited to case reports [13, 14] . An oral preparation of prednisolone has been recently licensed in the UK and the use of oral glucocorticoids in equine practice is likely to increase as a result. It is therefore important that veterinary surgeons and horse-owners have reliable, evidence-based assessments of the risks associated with the use of these drugs.
This retrospective case-control study aimed to quantify the incidence of laminitis following treatment with oral prednisolone and to identify potential horse-level factors associated with laminitis.
Materials and methods
Clinical records of horses registered with the ambulatory service at Liphook Equine Hospital between January 2001 and November 2014 were retrospectively reviewed to identify horses that had received treatment with oral prednisolone (Group P). Patient and clinical data were extracted and clinical and laboratory records reviewed. The age, sex, breed, reason for treatment, date of first prednisolone administration, prednisolone dose and duration of treatment, previous history of laminitis and results of investigations into endocrine disease were recorded, along with the date of the last known veterinary examination for each horse. For 83 horses in Group P, an approximate duration of treatment was recorded in the clinical records, therefore for data analysis the minimum number of treatment days was used. For the purposes of the study horses were considered to have equine metabolic syndrome (EMS) if they were reported to have hyperinsulinaemia, regional adiposity or obesity and to have pituitary pars intermedia dysfunction (PPID) if they displayed compatible clinical signs (including laminitis, hirsutism, fat redistribution, muscle wasting, lethargy, increased susceptibility to infection, polyuria and polydipsia) and had increased circulating concentrations of adrenocorticotropic hormone (ACTH). For horses that developed laminitis, additional data were collected: (1) date of onset of first episode of laminitis, and (2) outcome following laminitis.
For each horse treated with prednisolone, 2 time-matched controls were identified (Group C). Controls were horses treated by the same veterinary surgeon immediately before and after each case subject. Horses with laminitis at the time of the examination were excluded. Where horses examined before or after the case subject did not meet control inclusion criteria, preceding or subsequent horses were selected. In a small number in which the attending veterinary surgeon had not treated 2 other suitable control animals on the same day, horses treated by the closest matched colleague (matched by experience) on the same day were selected.
Data analysis
Statistical analyses were performed using commercial statistical software (SPSS Statistics for Windows Version 21) a and incidence rates compared using OpenEpi (version 3) b . In order to calculate days at risk, entry date for the study was defined as the date of commencing prednisolone therapy for Group P and date of veterinary visit for Group C. To calculate overall laminitis incidence rates, the end date was date of onset of laminitis and individual observations that did not get the outcome of interest were right censored at the date of last veterinary examination. To calculate incidence rate during prednisolone treatment, end date was date of onset of laminitis or observations were censored at the date of last prednisolone administration. As it was not possible to ascertain an exact date on which affected animals could be defined as 'laminitis-free' and therefore contributing further time in the population at risk, for animals with more than one episode of laminitis reported within the study period, only the first episode was included in analysis. The incidence rates of laminitis by treatment group, over the entire study period and during prednisolone treatment (where duration of treatment was recorded) were calculated and expressed as per 100 horse-years at risk with exact 95% confidence intervals (CI) around incidence rate estimates.
A Kaplan-Meier estimate of overall survivor function was performed and a Kaplan-Meier estimate of survivor function by group (prednisolonetreated or control), with log rank (Mantel-Cox) used to test the equality of survival distributions for the 2 groups. Survival distributions during the treatment period alone were also compared with the equivalent period in control horses.
Due to the low number of laminitis cases during the period of prednisolone administration, Cox regression analysis was performed using data from the entire study period in order to avoid the potential for introduced bias due to a low number of events per variable. Prior to univariable analysis, all variables were assessed for correlation using Spearman's rank correlation coefficients. Univariable analysis was performed using Cox proportional hazards models and all variables with a P value <0.3 were included in a multivariable Cox proportional hazards model, which was constructed using a stepwise backward elimination procedure. Continuous variables were assessed for linearity by conversion to categories and examination of the shape of the relationship with the outcome [15] . The age category of 6-10 years was selected as the reference category based on sample size and lower risk of laminitis in younger horses. Variables remained in the model if they significantly improved the fit (P≤0.05) assessed using the likelihood ratio statistic, or if removal resulted in substantial change (>25%) to the effect of other variables.
The residual 2-way interaction terms for the variables remaining in the final model was assessed. The model diagnostics performed included partial residuals (Schoenfeld residual) plots to assess proportionality throughout the study period for all variables in the multivariable model. In addition, graphical assessment of log cumulative hazard plots for categorical variables was performed. Scaled changes in the regression coefficient for each observation (delta-betas) were used to evaluate potential leverage by individual observations for each variable [16] . The model was re-run excluding observations with large delta-beta values to evaluate their influence on parameter estimates. The critical probability for all analyses was set at 0.05.
Results

Descriptive data and laminitis rates
Group P comprised 416 horses treated for a range of conditions: dermatological (30.8%), respiratory (19.0%), hepatic (9.9%), intestinal (14.0%), neurological (7.0%), vascular (3.9%), or other (15.9%). Duration of treatment was determined for 194 horses and ranged from 1 to 1095 days (median 28.5 days; IQR 14-60 days). Starting dose of prednisolone (mg/kg bwt) was reported infrequently in clinical notes (n = 58); with 56 horses starting on 1 mg/kg bwt and 2 horses on 0.5 mg/kg bwt. Group C contained 814 horses; suitable time-matched controls treated on the same day could not be identified for 9 Group P horses. Horses in the study were treated by 32 different vets and there was no association between vet and mortality due to laminitis (P>0.9).
Age was available for 279 horses in Group P and 521 horses in Group C. Median age for Group P horses was 13 years; (IQR 8-18 years; range 6 weeks-35 years) which was not significantly different to Group C (median 13 years; IQR 9-18 years; range 1-39 years) (P = 0.5). Breed or type was recorded for 486 horses (Fig 1) and there was no significant difference in breed distribution between the prednisolone and control groups (P = 0.4).
Across both groups the most numerous were Thoroughbred/ Thoroughbred crosses (21.6%), Warmblood/Warmblood crosses (16.0%), Native/Native crosses (12.3%) and Welsh/Welsh crosses (10.3%). Sex was reported for 871 animals with no significant difference in sex distribution identified between groups (P = 0.7). Mares or fillies comprised 41.4%, geldings 55.2% and colts or stallions 3.3%.
The 1230 animals contributed a total of 1944 horse-years at risk (Group P 615.7 horse-years at risk and Group C 1327.8 horse-years at risk) and 62 animals were reported to have ≥1 episode of laminitis, representing an overall incidence (based on first reported episode of laminitis only) of 3.19 cases (95% CI 2.45-4.09) per 100 horse-years at risk (Fig 2) . Over the entire study period, 16 laminitis cases were reported within Group P, with an overall incidence of 2.60 (95% CI 1.49-4.22) cases per 100 horse-years at risk (Fig 3) . For the subset of 194 horses where duration of treatment was recorded, 7 laminitis cases were reported during prednisolone treatment (33.6 horse-years at risk) representing an incidence rate of 20.84 (95% CI 8.35-42.95) cases per 100 horse-years at risk.
Over the entire study period, 46 laminitis cases were reported within Group C, with an overall incidence of 3.46 (95% CI 2.54-4.62) cases per 100 horse-years at risk (Fig 3) . A total of 376 horses in Group C were matched to the subset of 194 Group P horses where duration of treatment was recorded and observations were right censored at the date of last prednisolone administration for their matched case, or last veterinary examination where this date preceded last prednisolone administration. This subset of control horses contributed 53.0 horse-years at risk and 3 laminitis cases were reported representing an incidence rate of 5.66 (95% CI 1.14-16.54) cases per 100 horse-years at risk.
Over the entire study period, the mean survival (nonoccurrence of laminitis) time AE standard error was 3794.1 AE 113.9 days for Group P and 3182.4 AE 94.5 days for Group C. During the period of prednisolone administration, mean survival was 1011.1 AE 41.2 days for Group P and 914.0 AE 147.1 days for Group C. The log rank test comparing survival curves during the period of prednisolone administration for Group P and the equivalent time at risk for Group C demonstrated a significant difference (P = 0.04) (Fig 4) . There was no significant difference between groups for the overall laminitis incidence rate (P = 0.8), the incidence rate during the period of prednisolone administration (P = 0.09), or the overall test of equality of survival distributions (difference in the probability of laminitis) (P = 0.3) (Fig 3) . Kaplan-Meier estimate of survivor function (nonoccurrence of laminitis) for a cohort of veterinary registered horses, ponies and donkeys, during the period of prednisolone administration for treated animals (Group P) or the equivalent time at risk for control animals (Group C) (control group n = 376 and prednisolone-treated group n = 194).
Factors associated with laminitis
Of the 62 animals with an episode of laminitis during the study period, 24.2% (n = 15) were subjected to euthanasia due to laminitis; 3 from Group P (3/416, 0.7%) and 12 from Group C (12/814, 1.5%). There was no association between prednisolone administration and mortality due to laminitis (P = 0.7).
A total of 46 horses in Group C developed laminitis during the study period. Reason for veterinary visit on the date of entry into the study was recorded for all 46 horses; 19 were seen for routine work (vaccinations, dental treatment or microchipping), 10 for lameness investigation, 5 for diagnostic imaging, 2 for wounds, 2 for ophthalmic conditions, 2 for unspecified re-examination, one for a dressing change, one for sedation for physiotherapy, one for diarrhoea, one for anorexia, one for a cough and one for swelling of the head.
For the 16 horses with laminitis in Group P, onset of laminitis was reported a median of 34.5 days (IQR 10.25-295.50; range 1-2163 days) following commencement of prednisolone therapy. In 7 cases laminitis developed during treatment; after 2, 6, 8, 17, 18, 30 and 147 days. In 2 cases, laminitis occurred within the first week following cessation of treatment and in 3 cases there was ≥1 month between cessation of treatment and onset of laminitis. In 4 cases the exact time between initiation of treatment and onset of laminitis could not be determined from the records. Reason for initiation of prednisolone treatment was known for 15 of the 16 horses. Of these, 6 were being treated for dermatological, 5 for respiratory, 3 for intestinal and one for hepatic conditions. There was no association between reason for prednisolone treatment and development of laminitis (P = 0.9).
A total of 6 of the 16 laminitic horses in Group P were investigated for underlying endocrine disease and were all found to have either PPID or EMS. One had been diagnosed with PPID 13 months prior to the instigation of prednisolone and developed laminitis despite treatment with pergolide. A total of 3 were investigated once the laminitis was controlled; one had EMS and 2 had PPID. The remaining 2 were investigated >12 months after the onset of laminitis and both were diagnosed with PPID. Within Group P, animals diagnosed with an endocrine disorder (EMS or PPID) had a significantly higher incidence of laminitis overall (7.86; 95% CI 2.53-18.33 cases per 100 horse-years at risk) compared with those not diagnosed with endocrine disease (1.99; 95% CI 0.99-3.56 cases per 100 horse-years at risk) (P = 0.02). However, the difference in incidence of laminitis between Group P animals with and without endocrine disease was not significantly different during the period of prednisolone administration (P = 0.2). In Group C, 33/46 (71.7%) horses were investigated for endocrine disease; 16/33 (48%) and 5/33 (15%) were diagnosed with PPID and EMS, respectively, 3/33 (9%) were considered to have both. Endocrine disease was not identified in 9/33 (27%). The prevalence of endocrine disorders was not significantly different between prednisolone-treated animals (8.4%) and controls (10.2%) (P = 0.3).
Results of univariable Cox regression of risk factors for laminitis are presented in Table 1 . Presence of PPID (P<0.001), EMS (P<0.001), previous history of laminitis (P<0.001) and increasing age (P = 0.009) were all found to be associated with increased risk of laminitis. Native breeds, pony breeds and donkeys were found to be at increased risk compared with 'other horse breeds' (P = 0.009). Results of multivariable Cox regression are presented in Table 2 . The 2-way interaction term for the 2 variables (age and presence of EMS) retained in the final model was not statistically significant. Evaluation of partial residuals for both variables and graphical assessment of log cumulative hazard plots for EMS demonstrated no evidence of nonproportionality. Removal of influential individual observations with large delta-betas had little effect on coefficients showing that the model was stable and all observations were retained. 
Discussion
In the population studied, oral prednisolone did not appear to increase the risk of development of laminitis. The study was performed in client-owned horses of diverse ages, breeds and disciplines representative of the general veterinary registered equine population [17] [18] [19] . The widely held belief that treatment with oral prednisolone, or other glucocorticoids is a major risk factor for laminitis may be misguided. Previously reported risk factors for the development of laminitis, aside from glucocorticoid treatment, include recent weight gain [20] or excessive body weight [21] , season [20, 22] , age [23] , sex [22, 23] , previous history of laminitis [20, 21] lameness post shoeing or trimming [20] and the presence of PPID, EMS or hyperinsulinaemia [7, 8, 20, 24, 25] . In the current study, treatment with prednisolone, presence of PPID or EMS, previous history of laminitis, age, sex, breed and primary disease were investigated as potential risk factors. The presence of endocrine disease, previous history of laminitis and increasing age were all found to carry an increased risk of developing laminitis on univariable analysis. In the multivariable analysis, only EMS and age remained in the final model. Regrettably, the retrospective nature of the study and incomplete clinical records prevented scrutiny of other risk factors and analysis of the potential for their interaction in the development of laminitis.
In this study, all of the laminitic horses investigated for endocrine disease (n = 6) in Group P and 24/33 horses investigated for endocrine disease in Group C were diagnosed by the attending clinician with either PPID or EMS. Therefore, a total of 30/39 (77%) of the horses investigated had underlying endocrine disease, consistent with previous reports [26, 27] . The endocrine diseases PPID and EMS may be risk factors for laminitis by virtue of their effects on insulin sensitivity [7, 28, 29] , a theory supported by the finding that laminitis can be induced secondary to hyperinsulinaemia in healthy horses and ponies [8, 25] . Similarly, glucocorticoids may cause hyperinsulinaemia and insulin resistance due to inhibition of glucose uptake into muscle and adipose tissue, as well as by stimulation of gluconeogenesis [2, 30] . Administration of triamcinolone acetonide, for example, has been shown to induce prolonged hyperglycaemia and hyperinsulinaemia when administered by either intravascular or intramuscular routes [11] . Hence, the risk of prednisolone-associated (and possibly other glucocorticoid-associated) laminitis may be higher in patients with underlying endocrine disease [3] . The proportion of horses investigated for endocrine disease in Group P was lower than in Group C which may have been because it was assumed that the prednisolone was the sole cause of the laminitis. Although numbers were small, the finding that all the prednisolone-treated horses with laminitis for which diagnostic testing was undertaken also had EMS or PPID supports the value of investigating underlying endocrine disease in horses with corticosteroidinduced laminitis. The incidence of laminitis was not significantly increased during prednisolone administration in animals with existing endocrine disease in this study. However, further investigations are warranted to determine whether there is merit in testing for PPID and EMS prior to the instigation of treatment with prednisolone or other glucocorticoids.
The overall incidence of laminitis in this study was 3.19 cases per 100 horse-years at risk with a prevalence of 5.0% (62/1230); higher than the 0.5 cases per 100 horse-years at risk or 0.49% prevalence reported in a recent prospective cohort study of equine laminitis in Great Britain [31] . In the current study, all the horses were being attended by a veterinary surgeon. Around two-thirds of horses in the study were attended for a clinical complaint (the remaining third being seen for elective or preventive healthcare reasons), therefore the frequency of other diseases and the likelihood of management changes that may present a risk for laminitis will have been higher in the study population than in the general equine population and this may account for the higher prevalence than in the previous study by Wylie et al. [20] . A recent systematic review of frequency estimates for laminitis identified only 2 other studies of the general equine population [32] : in an Australian study of Pony Club horses and ponies, 23.8% of 84 horses developed laminitis over a one year period [33] , while an American study reported laminitis in 1.5% of 3582 horses over a 6.5 year period [34] . The wide variation between estimates of laminitis frequency is likely to reflect differences in study population and the complicated multifactorial nature of the disease.
A major limitation of this study was the absence of complete patient and clinical data which prevented a more rigorous investigation of the risk factors for laminitis in horses treated with glucocorticoids and potential interactions between them. Although no significant difference in prevalence of endocrine disease was identified between prednisolonetreated and control groups, a concern was the potential for bias as a result of the attending veterinary surgeons' perception of increased laminitis risk in horses with signs suggestive of PPID or EMS and hence reluctance to use prednisolone in such cases. Effects of prednisolone dose warrant further investigation. Additionally, the number of days of prednisolone treatment was estimated from clinical records in a proportion of horses for which duration of treatment was recorded, resulting in an underestimation of the time at risk contributed during treatment and therefore a subsequent overestimation of the laminitis incidence rate in this subset. Further research is required to corroborate these findings, to investigate interactions with other risk factors for laminitis, (particularly the presence of endocrine disease) and to determine whether other widely used glucocorticoids, such as dexamethasone, present a risk for the development of laminitis.
In conclusion, the findings of this retrospective, controlled study in a general veterinary registered equine population do not support the assertion that oral prednisolone administration increases the risk of laminitis.
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